MANUFACTURING ARTICLES
-
![new drugs by genome editing-GettyImages-1407089196]( "RNA Manufacturing Foundations: From DNA Templates To In Vitro Transcription (Pt. 1)")
RNA Manufacturing Foundations: From DNA Templates To In Vitro Transcription (Pt. 1)Cell-free RNA production is reshaping biomanufacturing through modular IVT workflows, advanced capping strategies, and scalable DNA template design.
-
![Molecular biology, mRNA strands, genetics-GettyImages-2198118160]( "Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing Efficiency")
Engineering RNA Payload Distribution In LNPs To Unlock Higher In Vivo Gene Editing EfficiencyNew research shows RNA payload distribution inside LNPs — not just encapsulation efficiency — may be key to unlocking stronger in vivo gene editing performance.
-
![Virus, pathogen, bacteria, biotechnology, bacterium, biolaboratory, new X disease, brain illness-GettyImages-1955429813]( "RNA Modification-Mediated Translational Control In Immune Cells")
RNA Modification-Mediated Translational Control In Immune CellsExploring how m6A RNA modifications control immune cell translation, influencing inflammation, tumor immunity, T cell activation, and future immunotherapies.
-
![BPO-Modulus-IMG_1]( "Repeating Sanofi's Ballroom Design On Two Continents")
Repeating Sanofi's Ballroom Design On Two ContinentsMoveable walls and a stunning number of robotics at its sites in France and Singapore, among other features, has earned Sanofi international recognition for innovation.
-
![DNA abstract-GettyImages-2223439582]( "Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic Disease")
Suppressor tRNA Therapeutics: A New Frontier In Treating Genetic DiseaseSuppressor tRNAs could unlock a scalable new way to treat genetic diseases caused by nonsense mutations, restoring full-length proteins across multiple indications.
-
![Virus, microscopy, vaccine, covid-GettyImages-1439691672]( "Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune Reset")
Engineering Transient In Vivo CAR-T: Extending Expression, Expanding Access, And Rethinking Immune ResetIn this Q&A, Michael Lam, Ph.D., explores how circular RNA and targeted delivery extend transient CAR expression to enable deep B-cell depletion and controllable immune reset.
MANUFACTURING VIDEOS
In this segment of the Bioprocess Online Live event mRNA Manufacturing: Bright Future, Big Challenges, we get to know leaders at three organizations bringing mRNA technology to bear in a variety of prophylactic and therapeutic capacities. Tune in and get to know Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx.
Sanofi’s Sumit Luthra shares several of the analytical and manufacturing innovations/improvements he’s watching and waiting for that will improve our knowledge of LNP composition, structure, function, and quality.
Fill and finish demands precision, compliance, and adaptability. Learn how flexible solutions and expert support can help you overcome complexity, reduce risk, and ensure quality in this final step.
As Pfizer and Moderna publicly announce work on an mRNA-based universal flu vaccine, what else is on the horizon for mRNA? Tune in to this segment from the Bioprocess Online Live event mRNA Manufacturing: Bright Future, Big Challenges for a discussion with Roberta Duncan, VP of the mRNA program at Seqirus; Duke Human Vaccine Institute Associate Director of Upstream and Downstream Process Development Jason Dickens, Ph.D.; and Jin Zhou, Executive Director of Process Development for mRNA and Protein Biologics at Ultragenyx. In this clip, they share market forecasts for mRNA vaccines and therapeutics and their companies’ go-forward plans to meet those demands.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![GettyImages-1026593952 tablet, data]( "Difco TC Yeastolate Ultra-Filtered (TCY UF) In Scale-Up Optimization")
Explore how Difco™ TC Yeastolate ultra-filtered (TCY UF) enabled over 100% improvement in titer for CHO cell culture through feed optimization and bioreactor scalability in a real-world application.
-
![Getty Images-823447656-vector-viral-lab-AAV-cell-development]( "CAR T Set The Pace So All Can Win The Cell Therapy Race")
Gain insight into the modest origins of cell therapy manufacturing and how this history has paved the way for future advancements from Bill Shingleton, R&D Leader at Cytiva.
-
![iStock-909908830]( "Navigating The Regulatory Maze: Fundamentals For Drug Development")
Learn about key regulatory concepts and ways to accelerate and reduce risk throughout the drug development journey.
-
![GettyImages-533059254-rna-dna-strand-light]( "Optimizing siRNA Therapeutics: Addressing Manufacturing Complexities")
Discover key strategies to optimize siRNA therapeutics by addressing critical nonclinical and manufacturing challenges for a smoother path to commercialization.
-
The transfer of mAb production processes between scales is difficult. In this study, we leveraged existing physical characterization data and scaled a process from microbioreactor to production scale.
-
![MRNA Technology-GettyImages-1366661187]( "Developing An mRNA-Encoded Antibody Platform To Accelerate Therapies To Clinic")
In this paper, we present the foundation of an mRNA-LNP platform for encoding and expressing therapeutic antibodies in vivo, eliminating the need for costly and time-consuming manufacturing.
-
![GettyImages-1731147638 research, cell culture]( "Enhanced mAb Production With High-Intensity Perfusion CHO Medium")
Reach new heights in mAb production with a high-intensity perfusion CHO medium designed to support consistently high product yield and quality in continuous perfusion cultures using CHO-K1 cells.
